Blackstone Inc
STOK icon

Blackstone Inc’s Stoke Therapeutics STOK Stock Holding History

Blackstone Inc’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,579
Closed -$996K – 664
2026
Q1 		$996K Buy
+30,579
New +$1M ﹤0.01% 242
2019
Q3 		– Sell
-20,500
Closed -$598K – 91
2019
Q2 		$598K Buy
+20,500
New +$550K ﹤0.01% 83

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Blackstone Inc's STOK Position: Q2 2026 in Review

Blackstone Inc sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 30,579 shares — an estimated $996K sold.

Blackstone Inc first reported a position in STOK in Q2 2019 and held it in 2 quarters. The position peaked at $996K in Q1 2026. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Blackstone Inc reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Blackstone Inc sold 30,579 Stoke Therapeutics shares in Q2 2026, an estimated $996K.
  • Blackstone Inc first reported a position in Stoke Therapeutics in Q2 2019 and held it in 2 quarters.
  • Blackstone Inc's Stoke Therapeutics position peaked at $996K in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.